Redeye is disappointed by Isofol’s phase III AGENT trial failing to meet its primary ORR and key sec...
Q2 bjöd på fortsatt god efterfrågan från flertalet stora kunder, trots osäker makromiljö.
Profit before tax came in 8% above ABGSC Strong quarter in the insurance business Guidance for ’2...
Q2 NII, NCI and insurance income came in as expected.
Suominen reports Q2 results on Tue, Aug 9. We continue to expect q/q improvement over the weak Q1 re...
DT’s Q2 EBIT faced a significant decline due to low sales and increased costs.
Redeye comments on EG7 ahead of its Q2-results (due 23 August) where we expect stable performance dr...
CapMan reported Q2 EBIT of 14.1m, 11% above Refinitiv consensus.
Q2: weaker profitability on lower GM and higher opex Continues to ramp up e-com investments Double...
Fastighetsbolaget har haft ett turbulent år och vi noterar att aktien handlas långt under rapportera...
Detection Technology’s Q2 net sales came down less than we expected.
Redeye comments on Better Collective ahead of its Q2-report (due 23 August) where we expect the typi...
Redeye is updating its estimates and valuation of Invisio after the Q2 report, which came in weaker ...
Continued focus on a diversified loan book Top-notch ROE expected to normalise at ~9% Expected div...
Infreas båda affärsområden visar goda resultat under första halvåret och fortsätter denna utveckling...
Redeye comments on Carasent’s deal in Norway yesterday, taking over customer agreements from Confrer...
NoHo upgraded its guidance on 22 June due to strong demand in the spring and early summer, as well a...
Redeye will not make any immediate adjustments following the lowered guidance for 2022 from Remedy.
Redeye is encouraged to see another quarter in which IRRAS continues to lay the building blocks for ...
Finally, Biovica has secured US approval (510k) for DiviTum in the core market indication.
